DisGeNET - a database of gene-disease associations

Leukemia, Myelocytic, Acute, C0023467

Variant: rs121909646 ×

Source: ALL

Results per page

Gene

Disease

Variant

Source

Association Type

Semantic type

Protein Class

Disease Class

Type

Original DB

Consequence

DSI _v

DPI _v

pLI

EI _vda

EL _gda

Score _vda

PMID

PMID Year

AF_EXOME

Num. PMIDs

Num. SNPs_gda

AF_GENOME

Variant

Gene

Risk Allele

Score _vda

Association Type

Original DB

Sentence supporting the association

PMID

PMID Year

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

25157968

2014

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Mutational landscape of AML with normal cytogenetics: biological and clinical implications.

23261068

2013

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

24046014

2013

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.

23714533

2013

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.

23783394

2013

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

23430109

2013

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

23321257

2013

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

23321257

2013

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.

23714533

2013

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

23430109

2013

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.

23783394

2013

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Mutational landscape of AML with normal cytogenetics: biological and clinical implications.

23261068

2013

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

22368270

2012

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia.

22504183

2012

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

22504184

2012

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia.

22504183

2012

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

22504184

2012

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

22368270

2012

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

20733134

2010

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

20733134

2010

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Recurring mutations found by sequencing an acute myeloid leukemia genome.

19657110

2009

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.

17606455

2007

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

16857985

2006

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

16857985

2006

dbSNP:

rs121909646

FLT3

0.700

CausalMutation

CLINVAR

Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.

14604974

2004